JPRN-UMIN000010055招募中2 期
Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy - Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy
Respiratory Center, Showa University Northern Yokohama Hospital0 个研究点目标入组 20 人开始时间: 2013年2月18日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with symptomatic brain metastases. 2. Patients with history or complication of hemoptysis. *Definition of hemoptysis is determined by the following. A history of continuous hemoptysis over one week, or hemoptysis receiving oral or intravenous hemostatic medicine. 3. Patients with a history of severe drug allergy. 4. Patients with uncontrolled ascites, pleural effusion, or pericardial effusion 5. Patients with a history of gastrointestinal perforation within an year, or a complication of uncontrollable peptic ulcer. 6. Patients with uncontrolled hypertension 7. Patients with infectious disease requiring systemic administration of antiviral agents, antifungal agents, or antibiotics. 8. Patients receiving anticoagulant therapy 9. Patients receiving antiplatelet therapy *Patients receiving aspirin therapy up to 325mg are allowed to be registered. 10. Patients with a history of radiation to the chest, or more than 20% region of bones with hematopoietic ability 11. Patients with multiple cancers within 5years prior to initiation of the study, except for carcinoma in situ, mucosal cancer appropriately treated non-melanoma, cervical cancer, thyroid cancer, early gastric cancer, early colorectal cancer. 12. Patients with serious complications (such as heart disease, active infection, interstitial pneumonia, diabetes) 13. Pregnant woman or those with suspected pregnancy, nursing woman and those who plan to become pregnant during the study period. 14. Other patients whom the investigation considers to be unsuitable for participation in the study. 15. Patients treated with EGFR-TKI
研究者
相似试验
招募中
2 期
Phase II study of multimodality treatment for ATRTAtypical teratoid rhabdoid tumorD016543JPRN-jRCTs051200071Junichi Hara50
招募中
2 期
Phase II study of new risk classification and high-dose chemotherapy for medulloblastomaJPRN-jRCTs051200021Hara Junichi229
尚未招募
2 期
Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.esophageal cancer, gastric cancer, small bowel cancer, colon cancer, pancreatic cancerJPRN-UMIN000049555ational Cancer Center Hospital30
招募中
2 期
Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositisJPRN-jRCTs062220023Takano HIdeyuki50
尚未招募
不适用
Phase II study to evaluate the safety and efficacy of endoscopic radiofrequency ablation of the bile duct using the Habib Endo HPB catheter in patients with unresectable cholangiocarcinoma after biliary stent placement.CholangiocarcinomaJPRN-UMIN000047127Yokohama City University10